Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study Arvinas' ARV-102 reduced LRRK2 protein in a Phase 1 trial, showing promising safety and pharmacodynamic outcomes for Parkinson's and PSP treatment.
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug The companies are looking to use protein degradation to take on some forms of breast cancer.
Tuesday's session: top gainers and losers Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.
Gapping stocks in Tuesday's session Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session.
Stay updated with the stocks that are on the move in today's pre-market session. As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients Arvinas and Pfizer share Phase 1b TACTIVE-U trial results showing 62.5% clinical benefit rate and tolerable safety for advanced breast cancer therapy.
ARVN Stock Earnings: Arvinas Beats EPS, Beats Revenue for Q2 2024 ARVN stock results show that Arvinas beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Biotech Arvinas Stock Earns 82 RS Rating The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82.
